Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
2. 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1h-benzimidazole
3. Aciphex
4. Dexrabeprazole
5. E 3810
6. E3810
7. Ly 307640
8. Ly-307640
9. Ly307640
10. Pariet
11. Rabeprazole
12. Sodium, Rabeprazole
1. 117976-90-6
2. Rebeprazole Sodium
3. Pariet
4. Aciphex
5. Rabeprazole Sodium Salt
6. Dexrabeprazole Sodium
7. Rabeprazole (sodium)
8. (s)-rabeprazole Sodium Salt
9. Aciphex Sprinkle
10. Ly307640 Sodium
11. Sodium Rabeprazole
12. Rabeprazole Sodium [usan]
13. Idiazole
14. Rabeprazole Na
15. Chebi:8769
16. 171440-19-0
17. Ly-307640
18. E3810
19. E-3810 Sodium
20. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
21. Ly-307640 Sodium
22. 3l36p16u4r
23. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
24. 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole Sodium Salt
25. Nsc-759270
26. Dsstox_cid_24205
27. Dsstox_rid_80118
28. Dsstox_gsid_44205
29. 1h-benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, Sodium Salt (1:1)
30. Rabicip
31. Pepcia
32. Aciphex Sodium
33. Ly 307640 Sodium
34. Habeprazole Sodium
35. Sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
36. Sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
37. Smr000550493
38. Cas-117976-90-6
39. Ncgc00159518-02
40. E 3810
41. Pariete
42. Unii-3l36p16u4r
43. Pariprazole Sodium
44. Dexrabeprazolesodium
45. Rebeprazole Sodium;
46. Aciphex (tn)
47. Pariet (tn)
48. Rebeprazole Sodium Salt
49. Rabeprazole Sodium- Bio-x
50. Mls001165734
51. Mls006010621
52. Schembl140494
53. Rabeprazole Na [vandf]
54. Chembl1200930
55. Dtxsid3044205
56. Rabeprazole Sodium [jan]
57. Hy-b0656a
58. Rabeprazole Sodium (jp17/usp)
59. Ex-a176
60. Hms2093h10
61. Hms2231e04
62. Hms3373b05
63. Rabeprazole Sodium [mart.]
64. Bcp06639
65. Rabeprazole Sodium [usp-rs]
66. Rabeprazole Sodium [who-dd]
67. Tox21_111736
68. Tox21_302317
69. Ac-715
70. Bdbm50247881
71. Mfcd02092688
72. Rabeprazole Sodium Salt [mi]
73. S4665
74. Rabeprazole Sodium, >=98% (hplc)
75. Akos015895734
76. Akos015962116
77. Akos025310160
78. Tox21_111736_1
79. Am81231
80. Ccg-213574
81. Ccg-268423
82. Nsc 759270
83. Rabeprazole Sodium [orange Book]
84. Ncgc00159518-05
85. Ncgc00255838-01
86. Rabeprazole Sodium [ep Monograph]
87. As-13338
88. Br167318
89. Rabeprazole Sodium [usp Monograph]
90. Ft-0631090
91. Ft-0689461
92. R0115
93. C07865
94. D00724
95. F17418
96. 976r906
97. Sr-01000799133
98. J-010726
99. Q-201655
100. Sr-01000799133-2
101. Q27108142
102. [2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
103. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole
104. 1h-benzimidazole,2-[[[4-(3-methoxypropoxy)- 3-methyl-2-pyridinyl]methyl]sulfinyl]-,sodium Salt
105. 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole, Sodium Salt
106. Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
Molecular Weight | 381.4 g/mol |
---|---|
Molecular Formula | C18H20N3NaO3S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 381.11230696 g/mol |
Monoisotopic Mass | 381.11230696 g/mol |
Topological Polar Surface Area | 81.5 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 446 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Aciphex |
PubMed Health | Rabeprazole (By mouth) |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | oral; Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Eisai; Eisai Medcl Res |
2 of 4 | |
---|---|
Drug Name | Rabeprazole sodium |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
3 of 4 | |
---|---|
Drug Name | Aciphex |
PubMed Health | Rabeprazole (By mouth) |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | oral; Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Eisai; Eisai Medcl Res |
4 of 4 | |
---|---|
Drug Name | Rabeprazole sodium |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
Treatment of duodenal ulcer, Treatment of gastric ulcer, Treatment of gastro-oesophageal reflux disease, Treatment of Helicobacter pylori in patients with peptic ulcer disease, Treatment of Zollinger-Ellison syndrome
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
60
PharmaCompass offers a list of Rabeprazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rabeprazole manufacturer or Rabeprazole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rabeprazole manufacturer or Rabeprazole supplier.
PharmaCompass also assists you with knowing the Rabeprazole API Price utilized in the formulation of products. Rabeprazole API Price is not always fixed or binding as the Rabeprazole Price is obtained through a variety of data sources. The Rabeprazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Rabeprazole sodium salt manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rabeprazole sodium salt, including repackagers and relabelers. The FDA regulates Rabeprazole sodium salt manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rabeprazole sodium salt API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rabeprazole sodium salt manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rabeprazole sodium salt supplier is an individual or a company that provides Rabeprazole sodium salt active pharmaceutical ingredient (API) or Rabeprazole sodium salt finished formulations upon request. The Rabeprazole sodium salt suppliers may include Rabeprazole sodium salt API manufacturers, exporters, distributors and traders.
click here to find a list of Rabeprazole sodium salt suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rabeprazole sodium salt DMF (Drug Master File) is a document detailing the whole manufacturing process of Rabeprazole sodium salt active pharmaceutical ingredient (API) in detail. Different forms of Rabeprazole sodium salt DMFs exist exist since differing nations have different regulations, such as Rabeprazole sodium salt USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rabeprazole sodium salt DMF submitted to regulatory agencies in the US is known as a USDMF. Rabeprazole sodium salt USDMF includes data on Rabeprazole sodium salt's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rabeprazole sodium salt USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rabeprazole sodium salt suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rabeprazole sodium salt Drug Master File in Japan (Rabeprazole sodium salt JDMF) empowers Rabeprazole sodium salt API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rabeprazole sodium salt JDMF during the approval evaluation for pharmaceutical products. At the time of Rabeprazole sodium salt JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rabeprazole sodium salt suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Rabeprazole sodium salt Drug Master File in Korea (Rabeprazole sodium salt KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Rabeprazole sodium salt. The MFDS reviews the Rabeprazole sodium salt KDMF as part of the drug registration process and uses the information provided in the Rabeprazole sodium salt KDMF to evaluate the safety and efficacy of the drug.
After submitting a Rabeprazole sodium salt KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Rabeprazole sodium salt API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Rabeprazole sodium salt suppliers with KDMF on PharmaCompass.
A Rabeprazole sodium salt CEP of the European Pharmacopoeia monograph is often referred to as a Rabeprazole sodium salt Certificate of Suitability (COS). The purpose of a Rabeprazole sodium salt CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Rabeprazole sodium salt EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Rabeprazole sodium salt to their clients by showing that a Rabeprazole sodium salt CEP has been issued for it. The manufacturer submits a Rabeprazole sodium salt CEP (COS) as part of the market authorization procedure, and it takes on the role of a Rabeprazole sodium salt CEP holder for the record. Additionally, the data presented in the Rabeprazole sodium salt CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Rabeprazole sodium salt DMF.
A Rabeprazole sodium salt CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Rabeprazole sodium salt CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Rabeprazole sodium salt suppliers with CEP (COS) on PharmaCompass.
A Rabeprazole sodium salt written confirmation (Rabeprazole sodium salt WC) is an official document issued by a regulatory agency to a Rabeprazole sodium salt manufacturer, verifying that the manufacturing facility of a Rabeprazole sodium salt active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rabeprazole sodium salt APIs or Rabeprazole sodium salt finished pharmaceutical products to another nation, regulatory agencies frequently require a Rabeprazole sodium salt WC (written confirmation) as part of the regulatory process.
click here to find a list of Rabeprazole sodium salt suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rabeprazole sodium salt as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rabeprazole sodium salt API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rabeprazole sodium salt as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rabeprazole sodium salt and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rabeprazole sodium salt NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rabeprazole sodium salt suppliers with NDC on PharmaCompass.
Rabeprazole sodium salt Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rabeprazole sodium salt GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rabeprazole sodium salt GMP manufacturer or Rabeprazole sodium salt GMP API supplier for your needs.
A Rabeprazole sodium salt CoA (Certificate of Analysis) is a formal document that attests to Rabeprazole sodium salt's compliance with Rabeprazole sodium salt specifications and serves as a tool for batch-level quality control.
Rabeprazole sodium salt CoA mostly includes findings from lab analyses of a specific batch. For each Rabeprazole sodium salt CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rabeprazole sodium salt may be tested according to a variety of international standards, such as European Pharmacopoeia (Rabeprazole sodium salt EP), Rabeprazole sodium salt JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rabeprazole sodium salt USP).